Dr. Rab Prinjha, VP, Head of Epigenetics - GlaxoSmithKline will present at the Epigenetics Discovery Congress

Dear Industry Expert,

We are pleased to inform you that Dr. Rab Prinjha, VP, Head of Epigenetics - GlaxoSmithKline will be presenting the key note address at the Epigenetics Discovery Congress in London on the 24th of September 2015.

At the Epigenetics Discovery Congress, Dr. Prinjha will be speaking about Epigenetics therapies in the clinical phase with special focus on:

  • Drugging the epigenome, entering the clinical phase
  • BET bromodomain inhibitors and their emerging pharmacology
  • Novel probes and their pharmacology across the “bromonome”, the next best BETs

Dr. Prinjha currently leads GSK's Epinova Epigenetics DPU and is co-chair of the GSK Biology Council and GSK’s observer of the Board of Padlock Therapeutics. Prior to leading this DPU he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterization along with coordinating academic collaborations that have resulted in a growing number of ground-breaking high-impact publications that he will discuss.

For more details, download agenda. Organizations who have confirmed their participation include:

  • Cellzome
  • Oryzon
  • Epizyme
  • Novartis
  • Erasmus University Rotterdams
  • Cancer Research UK
  • Diagenode
  • Active Motif
  • Cambridge Biomedical Centre
  • University of Oxford
  • Blizard Institute
  • Volition Rx
  • Celgene
  • Reaction Biology


If you would like to meet Dr. Prinjha and many other such epigenetic experts, sign up for the congress today.

We are currently providing an Early Registration discount of 15% on registration fees till 30th June 2015. Take advantage of the offer, register today with 'MnM-EDC-03' as your discount code.

I look forward to welcoming you at the congress.

Best regards,

Oliver Smith
MnM Conferences